白细胞介素-1阻滞剂在家族性地中海热肾移植受者中的疗效与安全性:倾向性评分匹配队列研究
回顾性队列纳入36例家族性地中海热合并AA淀粉样变的肾移植受者使用阿那白滞素或卡那奴单抗,经倾向性评分匹配36例无家族性地中海热/淀粉样变的受者作对照。研究组总体死亡更常见(19.4% vs 0%,P=.005),移植物丢失两组相当,5年和10年移植物生存率研究组更高。治疗期间每月发作次数、eGFR、hsCRP、ESR较治疗前降低,蛋白尿无变化。
要点
- 研究组总体死亡19.4% vs 对照组0%(P=.005),移植物丢失两组相当(27.8% vs 36.1%,P=.448)。
- 5年和10年移植物生存率研究组分别为94.4%和83.3%,高于对照组的77.8%和63.9%。
- 使用白细胞介素-1阻滞剂后每月发作次数、eGFR、hsCRP、ESR较治疗前降低,蛋白尿无变化。
主要发现
- 研究组总体死亡19.4% vs 对照组0%(P=.005)。
- 总体移植物丢失研究组27.8% vs 对照组36.1%(P=.448)。
- 5年移植物生存率研究组94.4% vs 对照组77.8%(P=.014),10年研究组83.3% vs 对照组63.9%(P<.001)。
- 活检证实的移植物排斥研究组8.3% vs 对照组25%,未达统计学显著(P=.058)。
- 与治疗前相比,使用白细胞介素-1阻滞剂后每月发作次数(P<.001)、eGFR(P=.004)、hsCRP(P<.001)和ESR(P=.026)水平在整个随访期间降低,蛋白尿水平未降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on use of interleukin (IL)-1 blockers in kidney transplant recipients (KTRs) with familial Mediterranean fever (FMF) are very limited. We aimed to evaluate the efficacy and safety of anakinra and canakinumab in the transplantation setting. METHODS: In this retrospective cohort study, we included KTRs who suffered from AA amyloidosis caused by FMF and treated with anakinra or canakinumab (study group, n = 36). Using propensity score matching, we selected 36 patients without FMF or amyloidosis from our database of 696 KTRs as the control group. Primary outcomes were patient and graft survival. Biopsy-confirmed graft rejection, changes in estimated glomerular filtration rate (eGFR), high-sensitivity CRP (hsCRP), erythrocyte sedimentation rate (ESR), proteinuria and number of monthly attacks were secondary outcomes. RESULTS: All KTRs with FMF began IL-1 blocker therapy with anakinra and nine (25%) were switched to canakinumab. Overall death was more frequent in the study group (19.4% vs 0%) (P = .005); however, overall graft loss was comparable between study (27.8%) and control groups (36.1%) (P = .448). Five- and 10-year graft survival rates were significantly higher in the study group (94.4% and 83.3%, respectively) than in the control group (77.8% and 63.9%, respectively) (P = .014 and P < .001, respectively). Rejections were numerically lower in study group (8.3% vs 25%), but it did not reach to statistical significance (P = .058). When compared with the pre-treatment period, with IL-1 blockers, the number of attacks per month (P < .001), and eGFR (P = .004), hsCRP (P < .001) and ESR (P = .026) levels were lower throughout the follow-up, whereas proteinuria levels were not. CONCLUSIONS: Anakinra and canakinumab are effective in KTRs suffering from FMF; however, the mortality rate may be of concern.
引用
- Mirioglu S, Dirim AB, Bektas M, et al. Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score-matched cohort study. Nephrol Dial Transplant. 2023. PMID: 36542475. doi:10.1093/ndt/gfac335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。